- Home
- ECAT vs QURE Comparison
ECAT vs QURE Comparison
Compare ECAT & QURE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ECAT | QURE |
|---|---|---|
| Founded | 2021 | 1998 |
| Country | United States | Netherlands |
| Employees | N/A | 248 |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 663.4M |
| IPO Year | 2021 | 2013 |
Fundamental Metrics
Financial Performance| Metric | ECAT | QURE |
|---|---|---|
| Price | $13.90 | $15.53 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 14 |
| Target Price | N/A | ★ $45.42 |
| AVG Volume (30 Days) | 560.5K | ★ 4.7M |
| Earning Date | 01-01-0001 | 06-02-2026 |
| Dividend Yield | ★ 9.20% | N/A |
| EPS Growth | N/A | ★ 29.67 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $13,107,000.00 |
| Revenue This Year | N/A | $126.14 |
| Revenue Next Year | N/A | $395.00 |
| P/E Ratio | $6.32 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $13.35 | $7.76 |
| 52 Week High | $17.14 | $71.50 |
Technical Indicators
Market Signals| Indicator | ECAT | QURE |
|---|---|---|
| Relative Strength Index (RSI) | 25.46 | 43.09 |
| Support Level | N/A | $13.29 |
| Resistance Level | $16.64 | $16.62 |
| Average True Range (ATR) | 0.23 | 2.08 |
| MACD | -0.07 | 0.25 |
| Stochastic Oscillator | 2.11 | 41.74 |
Price Performance
Historical ComparisonAbout ECAT BlackRock ESG Capital Allocation Term Trust of Beneficial Interest
BlackRock ESG Capital Allocation Trust is a non-diversified, closed-ended management investment company. The Trust's investment objectives are to provide total return and income through a combination of current income, current gains, and long-term capital appreciation.
About QURE uniQure N.V.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.